Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization

被引:50
作者
Aramwit, Pornanong [1 ]
Pruksananonda, Kamthorn [2 ]
Kasettratat, Narat [1 ]
Jammeechai, Karnphat [3 ]
机构
[1] Chulalongkorn Univ, Dept Pharm, Fac Pharmaceut Sci, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Fac Med, Bangkok 10330, Thailand
[3] Somdej Prapinklao Hosp, Inpatient Dept, Div Pharm, Bangkok, Thailand
关键词
buserelin acetate; dosage schedules; fertility agents; fertilization in vitro; gonadotropin chorionic; ovarian hyperstimulation syndrome; toxicity; urofollitropin;
D O I
10.2146/ajhp070566
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. A prospective observational study was conducted to identify risk factors for ovarian hyperstimulation syndrome (OHSS) in Thai patients using gonadotropins for in vitro fertilization. Methods. Outpatients receiving a short and a long protocol of ovarian stimulation with a recombinant follicle-stimulating hormone (rec FSH) at a Bangkok hospital were enrolled. Patients in the short protocol received rec FSH and the gonadotropin-releasing-hormone agonist buserelin acetate by subcutaneous injection after blood sampling on day 2 of the patient's cycle. When one or more follicles reached a diameter of 18 mm as determined by ultrasonography and the serum estradiol (E-2) concentration exceeded 400 pg/mL, patients received human chorionic gonadotropin (hCG); oocytes were retrieved 34-36 hours later. The long protocol differed only in that patients received nasal buserelin acetate and rec FSH 10 days before the cycle started and on day 2 of the cycle. Serum levels of E-2' luteinizing hormone, and FSH were monitored at baseline. In addition to E-2 concentration and follicle size and number, patients' weight, waist circumference, complete blood counts, and C-reactive protein (CRP) levels were monitored at intervals. Patients were instructed to notify the hospital of any symptoms of OHSS. Results. Of 117 patients enrolled, 13 had moderate OHSS and 1 had severe OHSS; all recovered. Patients with OHSS were significantly younger, had significantly lower body mass index, and had significantly higher E-2 before hCG injection, total number of follicles, total number of oocytes retrieved, and white blood cell and neutrophil counts after hCG injection. Patients with polycystic ovary syndrome were significantly more likely to have OHSS. CRP levels were higher in OHSS patients, but the difference was not significant. Multiple logistic regression showed that the combination of serum E-2 peak concentration of >= 4500 pg/mL and total number of oocytes retrieved of >= 15 predicted the occurrence of moderate-to-severe OHSS; 12 of 14 study patients who met these criteria had OHSS. Conclusion. Serum E-2 peak concentrations of >= 4500 pg/mL and total number of oocytes >= 15 may be useful indicators for identifying patients at high risk for moderate-to-severe OHSS.
引用
收藏
页码:1148 / 1153
页数:6
相关论文
共 34 条
[1]  
Abramov Y, 1996, HUM REPROD, V11, P1381
[2]   Decreasing the risk of severe ovarian hyperstimulation syndrome [J].
Al-Ramahi, M .
HUMAN REPRODUCTION, 1999, 14 (10) :2421-2422
[3]   Vascular endothelial growth factor, interleukin-6 and interleukin-2 in serum and follicular fluid of patients with ovarian hyperstimulation syndrome [J].
Artini, PG ;
Monti, M ;
Fasciani, A ;
Battaglia, C ;
D'Ambrogio, G ;
Genazzani, AR .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2002, 101 (02) :169-174
[4]   SEVERE OVARIAN HYPERSTIMULATION SYNDROME IN ASSISTED REPRODUCTIVE TECHNOLOGY - DEFINITION OF HIGH-RISK GROUPS [J].
ASCH, RH ;
LI, HP ;
BALMACEDA, JP ;
WECKSTEIN, LN ;
STONE, SC .
HUMAN REPRODUCTION, 1991, 6 (10) :1395-1399
[5]  
BLANKSTEIN J, 1987, FERTIL STERIL, V47, P597
[6]  
Budev Marie M, 2005, Crit Care Med, V33, pS301, DOI 10.1097/01.CCM.0000182795.31757.CE
[7]  
Buyalos RP, 1996, FERTIL STERIL, V65, P1
[8]   Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome [J].
Chen, CD ;
Chen, HF ;
Lu, HF ;
Chen, SU ;
Ho, HN ;
Yang, YS .
HUMAN REPRODUCTION, 2000, 15 (05) :1037-1042
[9]  
Danninger B, 1996, HUM REPROD, V11, P1597
[10]  
Daya Salim, 2004, Treat Endocrinol, V3, P161, DOI 10.2165/00024677-200403030-00004